File Download
 
Links for fulltext
(May Require Subscription)
 
Supplementary

Article: An update on targeting Hippo-YAP signaling in liver cancer
  • Basic View
  • Metadata View
  • XML View
TitleAn update on targeting Hippo-YAP signaling in liver cancer
 
AuthorsLiu, AM1
Xu, Z2
Luk, JM3 1 2
 
Issue Date2012
 
PublisherInforma Healthcare. The Journal's web site is located at http://www.expertopin.com/loi/ett
 
CitationExpert Opinion On Therapeutic Targets, 2012, v. 16 n. 3, p. 243-247 [How to Cite?]
DOI: http://dx.doi.org/10.1517/14728222.2012.662958
 
AbstractHepatocellular carcinoma (HCC) is an aggressive malignancy with approximately half a million cases diagnosed each year. Although strategies in surgical interventions have been investigated and applied, the prognosis is still poor. Novel chemotherapy for advanced stage HCC patients is still greatly in need. HippoYes-associated protein (YAP) signaling pathway controls organ size by regulating both cell proliferation and apoptosis during normal development. The pathway also has a prominent role in suppressing tumor growth, with the most evident contribution in HCC. In recent years, regulators of this pathway have gradually been revealed, providing new information for understanding this complex yet important growth-control signaling. This knowledge provides a basis for rational design of therapeutics against cancer that depends upon HippoYAP signaling for growth. © 2012 Informa UK, Ltd.
 
ISSN1472-8222
2013 Impact Factor: 4.901
2013 SCImago Journal Rankings: 2.101
 
DOIhttp://dx.doi.org/10.1517/14728222.2012.662958
 
ReferencesReferences in Scopus
 
DC FieldValue
dc.contributor.authorLiu, AM
 
dc.contributor.authorXu, Z
 
dc.contributor.authorLuk, JM
 
dc.date.accessioned2012-10-30T06:26:40Z
 
dc.date.available2012-10-30T06:26:40Z
 
dc.date.issued2012
 
dc.description.abstractHepatocellular carcinoma (HCC) is an aggressive malignancy with approximately half a million cases diagnosed each year. Although strategies in surgical interventions have been investigated and applied, the prognosis is still poor. Novel chemotherapy for advanced stage HCC patients is still greatly in need. HippoYes-associated protein (YAP) signaling pathway controls organ size by regulating both cell proliferation and apoptosis during normal development. The pathway also has a prominent role in suppressing tumor growth, with the most evident contribution in HCC. In recent years, regulators of this pathway have gradually been revealed, providing new information for understanding this complex yet important growth-control signaling. This knowledge provides a basis for rational design of therapeutics against cancer that depends upon HippoYAP signaling for growth. © 2012 Informa UK, Ltd.
 
dc.description.naturelink_to_subscribed_fulltext
 
dc.identifier.citationExpert Opinion On Therapeutic Targets, 2012, v. 16 n. 3, p. 243-247 [How to Cite?]
DOI: http://dx.doi.org/10.1517/14728222.2012.662958
 
dc.identifier.doihttp://dx.doi.org/10.1517/14728222.2012.662958
 
dc.identifier.epage247
 
dc.identifier.issn1472-8222
2013 Impact Factor: 4.901
2013 SCImago Journal Rankings: 2.101
 
dc.identifier.issue3
 
dc.identifier.pmid22335485
 
dc.identifier.scopuseid_2-s2.0-84863298936
 
dc.identifier.spage243
 
dc.identifier.urihttp://hdl.handle.net/10722/173030
 
dc.identifier.volume16
 
dc.languageeng
 
dc.publisherInforma Healthcare. The Journal's web site is located at http://www.expertopin.com/loi/ett
 
dc.publisher.placeUnited Kingdom
 
dc.relation.ispartofExpert Opinion on Therapeutic Targets
 
dc.relation.referencesReferences in Scopus
 
dc.subject.meshAnimals
 
dc.subject.meshCarcinoma, Hepatocellular - Metabolism
 
dc.subject.meshHumans
 
dc.subject.meshIntracellular Signaling Peptides And Proteins - Metabolism
 
dc.subject.meshLiver Neoplasms - Metabolism
 
dc.subject.meshNuclear Proteins - Metabolism
 
dc.subject.meshProtein-Serine-Threonine Kinases - Metabolism
 
dc.subject.meshSignal Transduction
 
dc.subject.meshTranscription Factors - Metabolism
 
dc.titleAn update on targeting Hippo-YAP signaling in liver cancer
 
dc.typeArticle
 
<?xml encoding="utf-8" version="1.0"?>
<item><contributor.author>Liu, AM</contributor.author>
<contributor.author>Xu, Z</contributor.author>
<contributor.author>Luk, JM</contributor.author>
<date.accessioned>2012-10-30T06:26:40Z</date.accessioned>
<date.available>2012-10-30T06:26:40Z</date.available>
<date.issued>2012</date.issued>
<identifier.citation>Expert Opinion On Therapeutic Targets, 2012, v. 16 n. 3, p. 243-247</identifier.citation>
<identifier.issn>1472-8222</identifier.issn>
<identifier.uri>http://hdl.handle.net/10722/173030</identifier.uri>
<description.abstract>Hepatocellular carcinoma (HCC) is an aggressive malignancy with approximately half a million cases diagnosed each year. Although strategies in surgical interventions have been investigated and applied, the prognosis is still poor. Novel chemotherapy for advanced stage HCC patients is still greatly in need. HippoYes-associated protein (YAP) signaling pathway controls organ size by regulating both cell proliferation and apoptosis during normal development. The pathway also has a prominent role in suppressing tumor growth, with the most evident contribution in HCC. In recent years, regulators of this pathway have gradually been revealed, providing new information for understanding this complex yet important growth-control signaling. This knowledge provides a basis for rational design of therapeutics against cancer that depends upon HippoYAP signaling for growth. &#169; 2012 Informa UK, Ltd.</description.abstract>
<language>eng</language>
<publisher>Informa Healthcare. The Journal&apos;s web site is located at http://www.expertopin.com/loi/ett</publisher>
<relation.ispartof>Expert Opinion on Therapeutic Targets</relation.ispartof>
<subject.mesh>Animals</subject.mesh>
<subject.mesh>Carcinoma, Hepatocellular - Metabolism</subject.mesh>
<subject.mesh>Humans</subject.mesh>
<subject.mesh>Intracellular Signaling Peptides And Proteins - Metabolism</subject.mesh>
<subject.mesh>Liver Neoplasms - Metabolism</subject.mesh>
<subject.mesh>Nuclear Proteins - Metabolism</subject.mesh>
<subject.mesh>Protein-Serine-Threonine Kinases - Metabolism</subject.mesh>
<subject.mesh>Signal Transduction</subject.mesh>
<subject.mesh>Transcription Factors - Metabolism</subject.mesh>
<title>An update on targeting Hippo-YAP signaling in liver cancer</title>
<type>Article</type>
<description.nature>link_to_subscribed_fulltext</description.nature>
<identifier.doi>10.1517/14728222.2012.662958</identifier.doi>
<identifier.pmid>22335485</identifier.pmid>
<identifier.scopus>eid_2-s2.0-84863298936</identifier.scopus>
<relation.references>http://www.scopus.com/mlt/select.url?eid=2-s2.0-84863298936&amp;selection=ref&amp;src=s&amp;origin=recordpage</relation.references>
<identifier.volume>16</identifier.volume>
<identifier.issue>3</identifier.issue>
<identifier.spage>243</identifier.spage>
<identifier.epage>247</identifier.epage>
<publisher.place>United Kingdom</publisher.place>
</item>
Author Affiliations
  1. Yong Loo Lin School of Medicine
  2. Nanjing Medical University
  3. Roche RandD Center (China) Ltd